GLMD 주가 차트
GLMD 수입
Galmed Pharmaceuticals Ltd
$0.65
10.61%
$0.06
종가: May 14, 16:00:00 GMT-4
$0.57
-13.42%
$-0.08
프리마켓: May 15, 07:30:17 GMT-4
뒤로
Galmed Pharmaceuticals Ltd (GLMD) 수입
최신 수익 결과: Q3 '25
보고됨: 2025-11-26
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
GLMD의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Galmed Pharmaceuticals Ltd GLMD의 지난 분기 매출 실적은 어땠나요?
Galmed Pharmaceuticals Ltd의 매출 추정치는 얼마인가요?
Galmed Pharmaceuticals Ltd의 수익 품질 점수는 얼마인가요?
Galmed Pharmaceuticals Ltd는 언제 수익을 보고하나요?
Galmed Pharmaceuticals Ltd의 예상 수익은 얼마인가요?
Galmed Pharmaceuticals Ltd은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.5953
시가
$0.593
일일 범위
$0.5701 - $0.6999
52주 범위
$0.4111 - $2.34
거래량
1.0M
평균 거래량
2.1M
배당수익률
--
EPS(TTM)
-2.40
시가총액
$3.7M
GLMD란 무엇인가요?
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
